期刊文献+

^18氟-脱氧葡萄糖正电子发射计算机断层显像寻找未知原发灶肿瘤原发灶的临床价值 被引量:1

Detection of primary sites of unknown primary tumors using lSF-FDG PET-CT t
原文传递
导出
摘要 目的研究”氟一脱氧葡萄糖正电子发射计算机断层显像(^18F-FDGPET-CT)在寻找原发灶不明转移癌(CUP)患者原发灶中的临床价值。方法回顾性分析为寻找原发灶而行^18F-FDGPET.CT扫描的CUP患者48例,其中男28例,女20例;年龄41-82岁,平均(57±16)岁。依据转移癌部位不同将患者分为颈部淋巴结转移组(28例)及非颈部淋巴结转移组(20例),计算并比较^18F-FDGPET-CT诊断各组原发灶的灵敏度。结果^18F-FDGPET-CT寻找CUP患者原发病灶的灵敏度为66.7%(32/48),寻找颈部淋巴结转移CUP患者的灵敏度为78.6%(22/28),非颈部淋巴结转移CUP患者的灵敏度为50.0%(10/20);^18F-FDGPET-CT诊断颈部淋巴结转移组CUP患者原发灶的灵敏度与非颈部淋巴结转移组相比,差异有统计学意义(x。4.286,P〈0.05)。结论^18F-FDGPET-CT诊断CUP患者原发灶灵敏度较高,尤其适用于颈部淋巴结转移的CUP患者。、 Objective To determine the value of ^18F-FDG PET-CT in detecting the primary origin of cancer of unknown primary (CUP). Methods A total of 48 patients (age range 41-82 years, mean age of 57±16 years, 20 females) were retrospectively selected. All patients were diagnosed as CUP and were examined by lSF-FDG PET-CT scan. The patients were divided into cervical lymph node metastasis group (28 cases) and extra-cervical lymph node metastasis group (20 cases) according to different metastasis site. Sensitivity of ^18F-FDG PET-CT to detect primary tumor site was compared between these two groups. Results ^18F-FDG PET-CT detected primary tumors in 32 of 48 patients (66.7 %), the cervical lymph node metastasis tumoi's in 22 of 28 patients (78.6 %), and extra-cervical lymph node metastasis tumors in 10 of 20 patients (50.0 %). There was significant difference between cervical lymph node metastasis group and extra-cervical lymph node metastasis group (X2 = 4.286, P 〈 0.05). Conclusion ^18F-FDG PET-CT has a high sensitivity to detect primary Origin of CUP, especially for patients with cervical lymph node metastasis.
作者 王娟 赵铭
出处 《肿瘤研究与临床》 CAS 2012年第1期46-48,共3页 Cancer Research and Clinic
基金 山西省自然科学基金(2008011073-31)
关键词 肿瘤 未知原发灶 ^18氟一脱氧葡萄糖 正电子发射计算机断层显像 Neoplasms, unknown primary ^18F-FDG PET-CT
  • 相关文献

参考文献13

  • 1Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol, 2009, 69: 271-278.
  • 2Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol, 2007, 46: 592-601.
  • 3Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer, 2003, 39: 1990-2005.
  • 4Park IS, Yim 11, Kang WJ, et al. Detection of primary sites in unknown primary tumors using FDG-PETor FDG-PET/CT. Bio Med Central Mar, 2011, 4: 56.
  • 5Seve P, Sawyer M, Hanson 1, et al. The influence of comorhidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer, 2006, 106: 2058-2066.
  • 6Kwee TC, Basu S, Chenq G, et al. FDG PET/CT in carcinoma of unknown primary. Eur 1 Nucl Med Mol Imaging, 2010, 37: 635-644.
  • 7Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer, 1994,73: 3047-3058.
  • 8Gutzeit A, Antoch G, Kuhl H, et al. Unknown primary tumors: detection with dual-modality PET/CT-initial experience. Radiology, 2005,234: 227-234.
  • 9Nomori H, Watanabe K, Ohtsuka T, et al. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer, 2004,45: 19-27.
  • 10Zhang M, Jiang X, Zhang M, et al. The role of 18F -FDG PET/CT in the evaluation of ascites of undetermined origin. 1 Nucl ~ed, 2009, 50: 506-512.

二级参考文献16

  • 1李亚军,高硕,陈秋松,李彦生,邢喜玲.^(18)F-FDGPET/CT显像探测原发肿瘤病灶的临床价值[J].中华核医学杂志,2005,25(1):37-38. 被引量:10
  • 2van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992[J]. Eur J Cancer, 2002, 38(3): 409-413.
  • 3Abruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients[J]. J Clin Oncol, 1994, 12(6): 1272-1280.
  • 4Seve P, Sawyer M, Hanson J, et al. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study[J]. Cancer, 2006, 106(9): 2058-2065.
  • 5Seve P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2- [F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site [J]. Cancer, 2007, 109 (2): 292-299,
  • 6Zhao J, Lin XT, Guan YH, et al. Detection of unknown primary tumor using whole body FDG PET [J]. Chinese-German J Clin Oncol, 2003, 2(3): 179-183.
  • 7Hany TF, Steinert HC, Goerres GW, et al. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results[J]. Radiology, 2002, 225(2): 575-581.
  • 8Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET Ⅲ", 21 July and 19 September 2000[J]. Eur J Nucl Med, 2001,28(11): 1707-1723.
  • 9Pelosi E, Pennone M, Deandreis D, et al. Role of whole body positron emission tomography/computed tomography scan with ^18F- fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site [J]. Q J Nucl Med Mol Imaging, 2006, 50(1): 15-22.
  • 10Gutzeit A, Antoch G, Kuhl H, et al. Unknown primary tumors: detection with dual-modality PET/CT--initial experience[J]. Radiology, 2005, 234(1): 227-234.

共引文献8

同被引文献15

  • 1Wolf FJ,Dupuy DE,Machan JT,et al.Adrenal neoplasms:effectiveness and safety of CT-guided ablation of 23 tumors in 22 patients[J].Eur J Radiol,2012,81:1717-1723.
  • 2Gnannt R,Fischer M,Goetti R,et al.Dual-energy CT for characterization of the incidental adrenal mass:preliminary observations[J].Am J Roentgenol,2012,198:138-144.
  • 3Siegelman ES.Adrenal MRI:techniques and clinical applications[J].J Magn Reson Imaging,2012,36:272-285.
  • 4Li Y J,Li ZM,Xia XY,et al.Prognostic value of interim and posttherapy 18F-FDGPET-CT in patients with mature T-cell and natural killer cell lymphomas[J].J Nucl Med,2013,54:507-515.
  • 5Chow A,Phillips M,Siew T,et al.Prognostic nomogram for diffuse large B-cell lymphoma(DLBCL) incorporating the international prognostic index(IPI) with interim-positron emission tomography(interim-PET) findings[J].Int Med J,2013,43:932-939.
  • 6Raghunandan V,Henry D,Yeung W,et al.Utility of PET-CT in differentiating benign from malignant adrenal nodules in patients with cancer[J].Am J Roentgenol,2008,191:1545-1551.
  • 7Sung YM,Lee KS,Kim BT,et al.18F-FDG PET versus(18)F-FDG PET/CT for adrenal gland lesion characterization:a comparison of diagnostic efficacy in lung cancer patients[J].Korean J Radiol,2008,9:19-28.
  • 8Choi YA,Kim CK,Park BK,et al.Evaluation of adrenal metastases from renal cell carcinoma and hepatocellular carcinoma:use of delayed contrast-enhanced CT[J].Radiol,2013,266:514-520.
  • 9Jana S,Zhang T,Milstein DM,et al.FDG-PET and CT characterization of adrenal lesions in cancer patients[J].Eur J Nucl Med Mol Imaging,2006,33:29-35.
  • 10Anderson SB,Webb MD,Banks KP,et al.Adrenal collision tumor diagnosed by F-18 fluorodeoxyglucose PET-CT[J].Clin Nucl Med,2010,35:414-417.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部